AnalystsInsight

Russell Stanley (Beacon): Analyst Track Record and Price‑Target Accuracy

How often Russell Stanley’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Russell Stanley ranks #794 of 1,000 analysts in Exent’s scoring (4.7★).
  • 0.0% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: — days; — of calls were up 12 months later.
  • Most‑covered stocks: CSE-CL, TRLV, CSE-GTII, TSX-OGI.
  • Free on Exent: Russell Stanley’s full record, with ratings 3 days after publication.

Russell Stanley’s track record at a glance

Russell Stanley of Beacon ranks #794 of the 1,000 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 0.0% of Russell’s price targets were reached, 52.4 points below the 52.4% average across all analysts.

MetricRussell StanleyAll analysts
Price‑target hit rate0.0%52.4%
Median days to hit target—91 days
Calls up after 12 months—64.0%
Median 12‑month return of calls—+13.4%
Hit rate, last 2 years0.0%—
Average worst drop after a call0.0%—
Ratings in the sample1—
Stocks covered18—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetRussell Stanley
Under 30 days—
30–90 days—
90–180 days—
Over 180 days—

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Russell Stanley covers most

StockRatings in the sample
CSE-CL40
TRLV39
CSE-GTII36
TSX-OGI32
TSX-WEED30
CSE-IAN29
CSE-TRUL18
TSX-CURA17

In the past year Russell’s ratings were 100% Buy, 0% Hold and 0% Sell.

Russell Stanley’s latest ratings

DateStockActionRatingPrice target
Jun 30, 2026TSX-FTGReiterated: BuyBuy$26.00
Jun 24, 2026TSX-MDAReiterated: BuyBuy$113.60
Jun 22, 2026GHMMaintained: BuyBuy$130.00
Jun 22, 2026GHMReiterated: BuyBuy$130.00
Jun 15, 2026TSX-MDAReiterated: BuyBuy$103.39
Jun 3, 2026TSXV-DEReiterated: BuyBuy$17.33
Jun 3, 2026TSXV-DEMaintained: BuyBuy$17.33
Jun 3, 2026TSXV-DEMaintainedBuy$17.07
May 21, 2026TSX-MCBReiterated: BuyBuy$5.50
May 21, 2026TSX-MCBMaintainedBuy$5.50
May 21, 2026TSX-MCBMaintained: BuyBuy$5.50
May 19, 2026TSX-MDAMaintainedBuy$101.72
  • Jun 30, 2026
    Stock
    TSX-FTG
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $26.00
  • Jun 24, 2026
    Stock
    TSX-MDA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $113.60
  • Jun 22, 2026
    Stock
    GHM
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $130.00
  • Jun 22, 2026
    Stock
    GHM
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $130.00
  • Jun 15, 2026
    Stock
    TSX-MDA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $103.39
  • Jun 3, 2026
    Stock
    TSXV-DE
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $17.33
  • Jun 3, 2026
    Stock
    TSXV-DE
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $17.33
  • Jun 3, 2026
    Stock
    TSXV-DE
    Action
    Maintained
    Rating
    Buy
    Price target
    $17.07
  • May 21, 2026
    Stock
    TSX-MCB
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $5.50
  • May 21, 2026
    Stock
    TSX-MCB
    Action
    Maintained
    Rating
    Buy
    Price target
    $5.50
  • May 21, 2026
    Stock
    TSX-MCB
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $5.50
  • May 19, 2026
    Stock
    TSX-MDA
    Action
    Maintained
    Rating
    Buy
    Price target
    $101.72

Russell’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Russell Stanley’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Russell Stanley ranks #794 of 1,000 with a 4.7★ rating. 0.0% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and — of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Russell Stanley’s success rate is 41.7% by the ranking source and 0.0% by Exent’s price-target hit-rate backtest, with a median of — days to reach a target.

Russell Stanley (Beacon) covers 18 stocks, mostly in healthcare. The most frequently rated are CSE-CL, TRLV, CSE-GTII, TSX-OGI, TSX-WEED.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.